SECUKINUMAB

SECUKINUMAB (10890E)

secukinumab 150 mg/mL injection, 1 mL pen device
10890E
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 4 Max qty units: 4 # of repeats: 0 DPMQ: $2,653.60 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10893H)

secukinumab 150 mg/mL injection, 1 mL pen device
10893H
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10895K)

secukinumab 150 mg/mL injection, 1 mL pen device
10895K
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10898N)

secukinumab 150 mg/mL injection, 1 mL pen device
10898N
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 2 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10900Q)

secukinumab 150 mg/mL injection, 1 mL pen device
10900Q
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 4 Max qty units: 4 # of repeats: 0 DPMQ: $2,653.60 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (10906B)

secukinumab 150 mg/mL injection, 1 mL pen device
10906B
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Continuing treatment

Restriction

Indication: Ankylosing spondylitis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (12297F)

secukinumab 150 mg/mL injection, 1 mL pen device
12297F
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (12307R)

secukinumab 150 mg/mL injection, 1 mL pen device
12307R
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $676.80 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx

SECUKINUMAB (12321L)

secukinumab 150 mg/mL injection, 1 mL pen device
12321L
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 1 (New patient)

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Non-radiographic axial spondyloarthritis
Treatment phase: Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 5 Max qty units: 5 # of repeats: 0 DPMQ: $3,289.78 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Cosentyx